针拨联合球结膜下注射丝裂霉素C治疗功能不良滤过泡

目的 探讨针拨联合丝裂霉素C(mitomycin C,MMC)球结膜下注射治疗青光眼患者小梁切除术后早期功能不良滤过泡的疗效.方法 对47例(50眼)小梁切除术后2～8周滤过泡功能不良青光眼患者行针拨联合MMC 0.2 mL(0.04 mg)结膜下注射,术后所有患者随访3～6个月,观察患者眼压、滤过泡形态和并发症.结果 小梁切除术后2～8周,低平、限局、肥厚、充血型滤过泡32眼、包囊型囊样滤过泡18眼.针拨联合MMC结膜下注射治疗后3～6个月,46眼的滤过泡转为功能性的,轻度膨隆弥散型31眼,多腔或薄壁型15眼,限局肥厚型或无滤过泡4眼.治疗前患眼的平均眼压为(28.5±6.5)mmHg(1 kPa=7.5 mmHg),随访3～6个月平均眼压为(16.3±2.9)mmHg,与注射前比较二者差异有统计学意义(P<0.05).46眼没有用抗青光眼药物或用一种抗青光眼药物眼压控制在21 mmHg以下,成功率占92%.治疗后视物模糊10眼,结膜下出血6眼,角膜上皮点状脱落2眼,无低眼压、伤口渗漏和前房变浅等并发症.结论 针拨联合MMC结膜下注射治疗小梁切除术后早期功能不良滤过泡是安全、有效、简单的方法.     

针拨联合球结膜下注射丝裂霉素C治疗新生血管性青光眼小梁切除术后功能不良滤过泡

目的 探讨针拨联合丝裂霉素C(MMC)球结膜下注射治疗新生血管青光眼小梁切除术后功能不良滤过泡的疗效.方法 对25例(25只眼)因新生青光眼行小梁切除术后滤过泡功能不良者,进行针拨联合MMC0.2 ml(0.04 mg)球结膜下注射,观察视力、眼压、滤过泡和副作用,并随访6～12个月.结果 小梁切除术后低平眼局肥厚充血型18只眼、包囊型囊样7只眼.针拨联合MMC结膜下注射治疗后6～12个月,轻度膨隆弥散型11只眼,多腔或薄壁型8只眼,眼局肥厚型或无滤过泡6只眼.治疗前患眼的眼压为(32.5±5.5)mmHg,随访结束时具有功能滤过泡眼的眼压为(18.2±3.4)mmHg.与针拨前比较两者差异有统计学意义(P<0.05).19只眼眼压下降有效,成功率占75%.治疗后结膜下出血3只眼,前房出血5只眼,无低眼压、伤口渗漏和脉络膜渗漏及浅前房等并发症.结论 针拨联合MMC结膜下注射治疗新生血管性青光跟小梁切除术后功能不良滤过泡是安全、有效、简单的方法.     

丝裂霉素C结膜下注射治疗青光眼小梁切除术后功能不良滤过泡的临床观察

目的观察丝裂霉素C(MMC)结膜下注射对青光眼小梁切除术后早期功能不良的滤过泡的临床效果。方法对114例(122只眼)青光眼患者术后1～8周内滤过功能不良的滤过泡行丝裂霉素C(MMC)结膜下注射,每天结膜下注射一次,共3～7次,MMC浓度为0.004%,配合每天眼部按摩2～3次,观察滤过泡弥散隆起的情况,前房深浅的变化,随访3～6个月。结果122只眼丝裂霉素C(MMC)结膜下注射前:低平限局肥厚充血型92只眼、包囊型囊样30只眼。MMC结膜下注射后滤过泡外观形态:轻度膨隆弥散型84只眼,多腔或薄壁型24只眼,限局肥厚型或无滤过泡14只眼。结膜下注射前患眼的眼压为(28.6±2.1)mmHg,结膜下注射后患眼的眼压为(15.1±2.3)mmHg。结论对于青光眼小梁切除术后早期功能不良的滤过泡采用结膜下注射丝裂霉素C(MMC)联合眼部按摩是安全、有效及简便的处理方法。     

针刺分离联合干扰素α-2b球结膜下注射治疗青光眼术后失败的滤过泡疗效观察

目的探讨青光眼滤过性手术后早期滤过泡功能丧失的处理方法及其效果。方法对25例(25只眼)小梁切除术后早期滤过泡功能丧失者,行针刺分离联合干扰素α-2b(IFNα-2b)球结膜下注射,随访观察6~12个月。结果治疗前平均眼压26.5mmHg,治疗后6个月平均眼压16.5mmHg,其中眼压降至10.5~20mmHg并形成功能性滤过泡者22只眼(88%)。结论针刺分离联合IFNα-2b球结膜下注射对早期滤过泡功能丧失者,可获得良好的效果,且操作简便、安全、无严重并发症。早期发现和处理是成功的关键。     

针刺分离联合5-FU治疗青光眼术后早期滤过泡功能不良

目的探讨对于青光眼术后早期功能不良的滤过泡采用针刺分离联合结膜下注射5-FU的治疗效果。方法青光眼滤过术后3月内25眼功能不良的滤过泡采用针刺分离滤过泡周围纤维瘢痕,联合结膜下注射5-FU 5mg/次,隔日1次,最多5次,分析治疗后眼压和滤过泡形态的变化及治疗后的眼部并发症。结果 25眼中,21眼眼压控制在21mmHg以下,其中18眼在15mmHg以下;滤过泡形态：有19眼表现为功能性滤过泡;并发症：常见并发症有结膜下出血、角膜上皮损伤、滤过泡损伤等。结论对于青光眼术后早期功能不良的滤过泡采用针刺分离联合结膜下注射5-FU是安全、有效的。     

针刺分离联合结膜下注射5-FU治疗青光眼术后早期滤过泡功能不良

目的:探讨对于青光眼术后早期功能不良的滤过泡采用针刺分离联合结膜下注射5-FU的治疗效果。方法:青光眼滤过术后3mo内25眼功能不良的滤过泡采用针刺分离滤过泡周围纤维瘢痕,然后结膜下注射5-FU5～10mg,隔日1次共5次,分析治疗后眼压和滤过泡形态的变化及治疗后的眼部并发症。结果:25眼中,21眼眼压控制在21mmHg以下,其中18眼在15mmHg以下;滤过泡形态:有19眼表现为功能性滤过泡;并发症:常见并发症有角膜上皮损伤、结膜下出血、滤过泡损伤等。结论:对于青光眼术后早期功能不良的滤过泡采用针刺分离联合结膜下注射5-FU是安全、有效的。     

针刺分离联合结膜下注射5-氟尿嘧啶治疗小梁切除术后功能不良滤过泡

目的：：探究针刺分离联合结膜下注射5-氟尿嘧啶治疗小梁切除术后功能不良滤过泡的临床效果。方法：选取行小梁切除术后1~4 wk来院复诊的青光眼患者26例30眼,对功能不良的滤过泡进行针刺分离联合膜下注射5-氟尿嘧啶进行治疗。观察滤过泡形态、眼压和并发症,随访3 mo。结果：针刺分离后滤过泡形态有24眼表现为功能性滤过泡。针刺分离前患者眼压为26.4±2.8mmHg,分离后眼压为14.1±1.1mmHg,两者差异有统计学意义(P<0.05)。治疗后治愈率70%(21眼),有效率17%(5眼),总有效率87%。常见并发症包括结膜下出血、角膜上皮点状剥脱和前房积血。结论：针刺分离联合结膜下注射5-氟尿嘧啶对小梁切除术后功能不良滤过泡有着良好效果,值得在临床治疗中推广应用。     

针刺分离术联合丝裂霉素C球结膜下注射治疗包裹性囊状滤过泡

目的 通过针刺分离术联合滤过泡旁注射丝裂霉素C(MMC)治疗小梁切除术后包裹性囊状滤过泡.方法 21例小梁切除术后并发包裹性囊状滤过泡的患者行针刺分离术后,滤过泡旁注射MMC,随访观察眼压和滤过泡形态.结果 治疗前平均眼压为29.77±3.76 mmHg,治疗后为18.95±5.49 mmHg,P＜0.01.治疗后Ⅰ型滤过泡5眼;Ⅱ型滤过泡12眼;Ⅲ型滤过泡4眼.结论 用此法治疗小梁切除术后包裹性囊状滤过泡有显著效果.     

反复针刺分离联合结膜下注射5-FU治疗青光眼术后滤过泡功能不良

目的:评估以反复针刺分离联合结膜下注射5-FU的方法处理青光眼术后功能不良滤过泡的效果。方法:回顾性分析2009-03/2013-02在我院以反复针刺分离联合结膜下注射5-FU的方法处理因青光眼术后滤过泡功能不良而眼压升高的连续病例34例34眼。分析治疗后眼压、滤过泡形态的变化及眼部并发症。结果:治疗后平均眼压从35.51mmHg降至14.43mmHg(P<0.05),成功率达91%。常见并发症包括角膜上皮损伤、结膜撕裂和脉络膜脱离等。结论:反复针刺分离联合结膜下注射5-FU的方法处理青光眼术后滤过泡功能不良安全有效。     

丝裂霉素C结膜下注射联合针拨治疗功能不良滤过泡

目的：探讨丝裂霉素C（ mitomycin C,MMC）结膜下注射联合针拨治疗青光眼小梁切除术后功能不良滤过泡的疗效。方法：对36例39眼因青光眼行小梁切除术后2～12 wk滤过泡功能不良者进行MMC 0．1mL（0．2mg／mL）结膜下注射联合针拨治疗,平均治疗1．31±0．58次,观察眼压、滤过泡和并发症．并随访3 mo。
　　结果：治疗后3mo时平均眼压为15．8±6．6mmHg,显著低于治疗前平均眼压27．4±5．7 mmHg;成功滤过泡32眼,成功率为82．1％。结膜下出血7眼,浅前房低眼压1眼,无伤口渗漏和脉络膜渗漏等并发症。
　　结论：MMC结膜下注射联合针拨治疗小梁切除术后功能不良滤过泡是安全、简单、有效的方法。     

针拨联合丝裂霉素C结膜下注射治疗抗青光眼术后失败滤过泡

目的:观察利用针拨联合丝裂霉素C结膜下注射治疗抗青光眼术后失败滤过泡的效果。方法:对抗青光眼小梁手术后3~22wk失败滤过泡34例(35眼)用针拨联合丝裂霉素C滤过泡旁注射,并随访6mo以上,观察滤过泡重新形成和眼压下降情况。结果:成功29例(29眼),手术前平均眼压为23.74±6.2mmHg,手术后眼压平均为13±4.3mmHg。其中3例(3眼)重复针拨、注射。随访期结束后统计针拨前后眼压具有显著性差异,Kaplan-Meier生存分析2a滤过泡成功率82.9%±6.4%。针拨术中有4眼前房出血,2眼低眼压,未见丝裂霉素的其它毒性反应。结论:针拨联合丝裂霉素C结膜下注射可以重新建立功能性滤过泡,有效地控制眼压,减少青光眼患者再次手术的痛苦。它是挽救抗青光眼术后失败滤过泡的一种良好的方法,具有毒性小、安全可重复的特点。     

Clinical study on interferon treatment of early scarring in filtering bleb

 Purpose: To investigate the effectiveness of needle revision combined with subconjuctival injection of interferon α-2b in reversing early scarring of filtering blebs following trabeculectomy surgery. Methods: Twenty-five  glaucoma patients (31 eyes) who presented with scarred or encapsulated filtering bleb after glaucoma surgery underwent needle revision in combination with subconjuctival injection of interferon α-2b, and were followed for 12 months. Intraocular pressure (IOP) and filtering bleb morphology were observed post treatment. Results: The mean time until scarring occurred was 21.0±7.4 days. The average time between recognition of bleb scarring and completion of needle revision was 2.2±0.8 days. The time interval between surgery and needle revision was inversely correlated with the time until needle revision (r = -0.694, P < 0.001). The mean IOPs before and after needle revision were 24.2±2.7mmHg and 19.6±3.8mmHg, respectively (t = 5.916,P < 0.001). At the 12-month follow-up visit, 18 eyes (58.1%) achieved complete success in IOP control, and 6 eyes (19.4%) had conditional success. The overall success rate for needling was thus 77.4%. Subconjunctival hemorrhage was observed in 4 eyes during the needle revision procedure. Punctate staining was found in the corneal epithelium of 2 eyes. Shallow  nterior chamber (Grade I or II) was identified in 5 eyes.  Conclusion: Slit-lamp needle revision combined with subconjunctival injection of interferon α-2b may be efficacious in the treatment of early scarring of filtering blebs, is easy and safe to perform, and may be considered for more widespread application.     

功能不良性滤过泡结膜下分离注射干扰素α-2b疗效观察

目的 评价针刺分离联合结膜下注射干扰素α-2b治疗青光眼小梁切除术后早期功能不良性滤过泡的有效性和安全性.方法 对23例(27只眼)小梁切除术后早期发生的功能不良性滤过泡行针刺分离联合干扰素α-2b结膜下注射,随访时间6个月以上,采用Van Buskirk裂隙灯显微镜分型法和Leung前节-OCT检查法相结合评估滤过泡治疗前后的形态和功能.结果 功能不良性滤过泡的发生时间为术后(51.04±23.09)d(19～89d).治疗前患眼眼压为(22.77±8.65)mmHg(10～45mmHg)),随访终点眼压为(16.68±3.37)mmHg(7.70～21mmHg),两者差异有统计学意义(P=0.002).治疗的完全成功率为66.67%(18只眼),条件成功率为25.93%为(7只眼),总有效率为92.6%.治疗的主要并发症为滤过泡区结膜下出血(37%)和结膜破裂(22.22%),治疗后无明显远期并发症.结论 针刺分离联合滤过区结膜下注射干扰素α-2b是治疗功能不良性滤过泡安全有效的方法,采用AS-OCT能客观、及时评估功能不良性滤过泡的形态和功能变化.     

难治性青光眼早期功能不良滤过泡处理的临床观察

目的：观察难治性青光眼小梁切除术后早期功能不良滤过泡的处理方法、治疗效果,探讨有效、安全的早期功能不良滤过泡处理方法。

方法：收集我院2006-01/2012-01诊断为难治性青光眼且行小梁切除术后出现早期功能不良滤过泡(或倾向)者20例20眼于小梁切除术后3～8d进行治疗,治疗方法包括：眼球按摩、断(或拆除)巩膜缝线后再行眼球按摩、钝针头针拨分离滤过泡或联合结膜下注射5-氟尿嘧啶(5-FU)。所有患者术中曾用过抗代谢药丝裂霉素C(MMC, 0.3g/L)。随访6mo。

结果：经眼球按摩后有9眼获得功能滤过泡,联合钝针头针拨分离滤过泡治疗后有5眼为功能滤过泡,4眼经联合5-FU结膜下注射后为功能滤过泡,其综合成功率达90%。治疗前平均眼压24.61±5.4mmHg(1mmHg=0.133kPa),随访6mo结束时平均眼压为15.20±4.8mmHg,治疗前后眼压差异有显著统计学意义(P<0.01)。操作中和操作后未见任何并发症。

结论：难治性青光眼病情复杂,小梁切除术后极易出现早期功能不良滤过泡(或倾向),我们提倡尽早处理,综合眼球按摩、断(或拆除)巩膜缝线、钝针头针拨分离滤过泡或联合结膜下注射5-FU更安全有效,可很大程度上挽救早期濒临失败的滤过泡,提高手术成功率。     

针刺分离联合5-氟尿嘧啶注射治疗功能不良滤过泡的临床观察

目的：观察针刺分离联合5-氟尿嘧啶(5-FU)结膜下注射治疗青光眼小梁切除术后不同时期功能不良滤过泡的临床疗效、影响因素及安全性。
　　方法：对76例83眼小梁切除术后功能不良滤过泡进行针刺分离联合5-FU 结膜下注射,针刺分离后随访12mo,对随访时患者的眼压( intraocular pressure,IOP)、用药次数、角膜内皮、滤过泡的形态及并发症进行观察记录。
　　结果：针刺分离前患者的眼压为35.3依5.8mmHg(1kPa =7.5mmHg),随访结束时眼压为17.0依4.3mmHg,两者差异有显著统计学意义(t =24.846,P<0.01);术前平均用药种类为1.7依0.9种,随访结束时平均用药种类为0.4依0.7种,两者差异有显著统计学意义(t =11.145,P<0.01)。针刺分离12mo 后滤过泡成功率为89.2%,其中完全成功率为69.9%,Kaplan-Meier 生存分析示83眼平均生存时间为11.0mo(95% CI：10.3~11.6)。青光眼的类型、滤过手术是否使用丝裂霉素 C(mitomycin C,MMC)、患者年龄及滤过手术至针刺分离的间隔时间对针刺分离效果无影响,针刺分离前滤过泡形态对针刺分离效果有影响,包囊型滤过泡较扁平型滤过泡针刺分离效果好,滤过手术后3mo 内进行针刺分离的患者比>3mo 的患者平均针刺分离的次数明显减少。
　　结论：针刺分离联合5-FU 结膜下注射是治疗小梁切除术后功能不良滤过泡的一种安全、有效的简单处理方法,小梁切除术后发现功能不良滤过泡应早期处理。     

Surgical management of encapsulated filtering blebs

Encapsulated filtering blebs associated with elevated intraocular pressure or symptomatic dellen formation, unresponsive to conservative therapy, developed in 24 of 222 eyes following glaucoma filtering surgery over a five-year period, an incidence of 11%. Nine of 13 eyes were treated successfully with primary needling of the bleb. Ten of 11 eyes were successfully treated with primary bleb revision. Four eyes were successfully treated with a combination of needling and surgical revision and one eye required cyclocryotherapy. The overall success rate of needling or bleb revision was 96% after an average follow-up of 20 months. Thus, encapsulation of the filtering bleb, although requiring additional surgery in many cases, carries a favorable long-term prognosis.     

Prospective evaluation of preoperative factors associated with successful mitomycin C needling of failed filtration blebs

PURPOSE: To study the long-term effectiveness and factors involved in successful needling of failed filtration blebs with mitomycin C (MMC). MATERIALS AND METHODS: We conducted a prospective, nonrandomized comparative trial that included 34 consecutive patients (34 eyes) who underwent mitomycin C needling of a failed filtering bleb after trabeculectomy followed by a 0.01 mL injection of mitomycin C (0.2 mg/ml). The success of the needling revision was defined as absolute if the intraocular pressure (IOP) was < 21 mm Hg without antiglaucoma medications and qualified if the IOP was < 21 mm Hg with antiglaucoma medications. Preoperative and perioperative factors were evaluated for an association with postoperative success using Kaplan-Meier survival analysis. RESULTS: The mean follow-up was 14.2 +/- 9.8 months. The mean preoperative IOP was 25.5 +/- 4.4 mm Hg, which decreased to 11.1, 13.4, 15.8, 16.7, 14.9, 14.1, 13.9, and 13 on postoperative day 1, postoperative week 1, and after 1, 3, 6, 9, 12, and 24 months, respectively (P = 0.001 for each comparison). At the final visit, success was absolute in 15 eyes (44.1%) and qualified in 14 eyes (41.2%). The success rates were 90% and 75% at 1 and 2 years, respectively. The success of the needling procedure was highly correlated with glaucoma filtration surgery performed less than 4 months previously (Kaplan-Meier analysis, log-rank test P = 0.006). CONCLUSIONS: Mitomycin C needling revision appears to have a high long-term success rate. Surgery performed less than 4 months previously contributes to the success of the initial mitomycin C needling procedure.     

Slit-lamp needle revision of failed filtering blebs using high-dose mitomycin C

PURPOSE: To investigate the efficacy of bleb needle revision with high-dose mitomycin C in reviving failed filtering blebs after 1 year. PATIENTS AND METHODS: We reviewed the charts of 44 patients with one eye that had undergone bleb needle revision with a mixture of 0.1 mL of mitomycin (0.4 mg/mL) mixed with 0.1 mL of non-preserved 1% lidocaine. At least 12 months of follow-up were required. A successful bleb needle revision was defined as one that did not require a subsequent needling, glaucoma surgery, or medication to reach an intraocular pressure (IOP) greater than 4 mm Hg but less than 22 mm Hg. A qualified success was defined as a successful bleb needle revision that required subsequent needling or medication. RESULTS: The bleb needle revision with high-dose mitomycin was a success or qualified success after 12 months in 28 patients or 64% (95% confidence interval, 50% to 78%). The baseline IOP in these patients was 26.7 +/- 8.2 mm Hg (range 15 to 48 mm Hg) using an average of 1.5 +/- 1.5 glaucoma medications. The IOP after 1 year was 13.6 +/- 4.0 (range 6 to 21 mm Hg) with an average of 0.5 +/- 0.8 medications. Of 44 patients, 17 (39%) were successes and 11 (25%) were qualified successes. CONCLUSION: Bleb needle revision with high-dose MMC was effective in reducing the IOP in 64% of eyes with a failed filtering bleb with minimal long-term complications.